National Cancer Institute Sponsored Trials

In November 2011, we entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute’s Cancer Therapy Evaluation Program (NCI-CTEP). The CRADA provides for as many as 20 active clinical trials each year for a five-year period, and the agreement reflects a commitment by NCI-CTEP to support the exploration of cabozantinib's potential in a wide variety of cancers. We believe that this agreement will allow us to broadly expand the cabozantinib development program and substantially increase the number of indications and disease settings in which cabozantinib is being investigated.

 

Status Tumor Types Trial Description Phase Trial Information
Recruiting Urothelial Cancer Phase II Study of XL184 in Patients with Advanced/Metastatic Urothelial Carcinoma Phase 2 NCT01688999
Recruiting Castration-Resistant Prostate Cancer Phase 1 Study of XL184 plus Docetaxel and Prednisone in Metastatic Castrate Resistant Prostate Cancer Phase 1 NCT01683994
Recruiting Soft Tissue Sarcomas Phase 2 Study of XL184 (Cabozantinib), a Dual Inhibitor of MET and VEGFR, in Patients with Metastatic Refractory Soft Tissue Sarcoma Phase 2 NCT01755195
Recruiting Pediatric Solid Tumors Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents with Recurrent or Refractory Solid Tumors, including CNS Tumors Phase 1 NCT01709435
Recruiting Ovarian Cancer A Randomized Phase 2 Study of Cabozantinib versus Weekly Paclitaxel in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Phase 2 NCT01716715
Recruiting Differentiated Thyroid Cancer Phase 2 Study of Cabozantinib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Who Failed Prior First-Line VEGFR-Targeted Therapy Phase 2 NCT01811212
Recruiting Endometrial Cancer Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer Phase 2 NCT01935934
Recruiting Non-Small Cell Lung Cancer A Randomized Phase 2 Trial of Erlotinib with or without Cabozantinib as 2nd or 3rd Line Therapy in Patients with EGFR Wild-type NSCLC Phase 2 NCT01708954
Recruiting Non-Small Cell Lung Cancer Randomized, Phase 2 Trial of XL184 (cabozantinib) Plus Erlotinib versus Erlotinib Alone in Patients with Advanced EGFR-Mutant Non-small Cell Lung Cancer (NSCLC) who have Progressed on Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy Phase 2 NCT01866410
Recruiting Renal Cell Carcinoma Randomized Phase 2 Study Comparing Cabozantinib with Commercially Supplied Sunitinib in Patients with Previously-Untreated Metastatic Renal Cell Carcinoma Phase 2 NCT01835158
Recruiting Uveal Melanoma Randomized Phase 2 Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma Phase 2 NCT01835145
Recruiting Melanoma Phase 1 Dose Escalation of the MET Inhibitor XL184 and Vemurafenib in Patients with BRAF Mutated Melanoma whom Have Progressed Immediately Prior on a BRAF Inhibitor Phase 1 NCT01835184
Recruiting Various Phase 1 Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Patients with HIV Phase 1 NCT01822522

 

For a detailed list of clinical studies posted on ClinicalTrials.gov please visit HERE. For further information regarding all clinical trials, please contact Exelixis Medical Information at 1-888-EXELIXIS (1-888-393-5494) or at druginfo@exelixis.com.